Page last updated: 2024-10-16

beta-alanine and Cachexia

beta-alanine has been researched along with Cachexia in 1 studies

Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.

Research Excerpts

ExcerptRelevanceReference
" In animals, 10d showed moderate to good oral bioavailability and promoted food intake in tumor-bearing mice after oral administration."1.34Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia. ( Arellano, M; Chen, C; Chen, CW; Chen, T; Fleck, BA; Foster, AC; Hoare, SR; Jiang, W; Johns, M; Joppa, M; Madan, A; Marinkovic, D; Markison, S; Sai, Y; Saunders, J; Tran, JA; Tucci, F; Wen, J, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, C1
Jiang, W1
Tucci, F1
Tran, JA1
Fleck, BA1
Hoare, SR1
Joppa, M1
Markison, S1
Wen, J1
Sai, Y1
Johns, M1
Madan, A1
Chen, T1
Chen, CW1
Marinkovic, D1
Arellano, M1
Saunders, J1
Foster, AC1

Other Studies

1 other study available for beta-alanine and Cachexia

ArticleYear
Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.
    Journal of medicinal chemistry, 2007, Nov-01, Volume: 50, Issue:22

    Topics: Administration, Oral; Animals; beta-Alanine; Biological Availability; Cachexia; Cyclic AMP; Dogs; Ea

2007